Moreno C, Byrd JC, Hillmen P, et al. Ibrutinib in previously treated chronic lymphocytic leukemia updated efficacy and safety of the RESONATE study with up to four years of follow-up. EHA 2017, abstract S769.
DHC 2022: Veel aanpassingen in nieuwe AML-richtlijn
feb 2022 | Leukemie